File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

postgraduate thesis: Role of ginsenoside Rb1 and its metabolite compound K in attenuating chemoresistance and tumour-initiating properties of ovarian cancer cells

TitleRole of ginsenoside Rb1 and its metabolite compound K in attenuating chemoresistance and tumour-initiating properties of ovarian cancer cells
Authors
Issue Date2014
PublisherThe University of Hong Kong (Pokfulam, Hong Kong)
Citation
Kala, S.. (2014). Role of ginsenoside Rb1 and its metabolite compound K in attenuating chemoresistance and tumour-initiating properties of ovarian cancer cells. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5334847
AbstractResistance to therapy by traditional chemotherapy drugs commonly seen in ovarian cancer has been a major hurdle to developing successful treatment for the disease. Such chemoresistance is attributable to a subpopulation of cells known as cancer stem/tumour-initiating cells (jointly CSCs) within tumours that display characteristics of self-renewal, differentiation abilities, and serve as the primary drivers of tumourigenesis. CSCs are highly associated with therapeutic failures such as recurrent tumours and metastases. The use of adjuvants to sensitise cells to the drugs is an important field of current research, and ginsenosides are a class of candidate molecules. Of the several types of ginsenosides, Rb1 is one of the most prevalent and active ingredients of ginseng; hence the effects of Rb1 and its metabolite compound K (CK) on CSCs were investigated. Treatment with Rb1 and CK was found to inhibit the ability of ovarian cancer cells to form spheroids when cultured as CSCs, and reduce their expression of stem cell markers, Oct-4 and Nanog, and genes involved in drug resistance, ABCG2 and P-glycoprotein (P-gp), in a dose- and time-dependent manner. More importantly, treatment of Rb1 or CK could potentiate the anti-tumour effect of the front-line chemotherapeutic drugs paclitaxel or cisplatin. The combined treatment of Rb1 or CK with paclitaxel or cisplatin significantly reduced tumour-sphere forming ability as well as the cell viability of ovarian CSCs. These effects were associated with decreases in the expression of epithelial-to-mesenchymal transition transcriptional regulators Snail and Slug, concomitant with a decrease of N-cadherin and an increase of E-cadherin known to regulate stem-like properties. There was also an increase in cleaved caspase-3 levels, suggesting that the observed growth inhibition was due to apoptosis. Together, these findings suggest that Rb1 or CK in combination with a chemotherapeutic regimen may be a promising approach in cancer therapy.
DegreeMaster of Philosophy
SubjectGinseng - Therapeutic use
Drug resistance in cancer cells
Ovaries - Cancer
Dept/ProgramBiological Sciences
Persistent Identifierhttp://hdl.handle.net/10722/221128

 

DC FieldValueLanguage
dc.contributor.authorKala, Shashwati-
dc.date.accessioned2015-10-30T23:11:18Z-
dc.date.available2015-10-30T23:11:18Z-
dc.date.issued2014-
dc.identifier.citationKala, S.. (2014). Role of ginsenoside Rb1 and its metabolite compound K in attenuating chemoresistance and tumour-initiating properties of ovarian cancer cells. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5334847-
dc.identifier.urihttp://hdl.handle.net/10722/221128-
dc.description.abstractResistance to therapy by traditional chemotherapy drugs commonly seen in ovarian cancer has been a major hurdle to developing successful treatment for the disease. Such chemoresistance is attributable to a subpopulation of cells known as cancer stem/tumour-initiating cells (jointly CSCs) within tumours that display characteristics of self-renewal, differentiation abilities, and serve as the primary drivers of tumourigenesis. CSCs are highly associated with therapeutic failures such as recurrent tumours and metastases. The use of adjuvants to sensitise cells to the drugs is an important field of current research, and ginsenosides are a class of candidate molecules. Of the several types of ginsenosides, Rb1 is one of the most prevalent and active ingredients of ginseng; hence the effects of Rb1 and its metabolite compound K (CK) on CSCs were investigated. Treatment with Rb1 and CK was found to inhibit the ability of ovarian cancer cells to form spheroids when cultured as CSCs, and reduce their expression of stem cell markers, Oct-4 and Nanog, and genes involved in drug resistance, ABCG2 and P-glycoprotein (P-gp), in a dose- and time-dependent manner. More importantly, treatment of Rb1 or CK could potentiate the anti-tumour effect of the front-line chemotherapeutic drugs paclitaxel or cisplatin. The combined treatment of Rb1 or CK with paclitaxel or cisplatin significantly reduced tumour-sphere forming ability as well as the cell viability of ovarian CSCs. These effects were associated with decreases in the expression of epithelial-to-mesenchymal transition transcriptional regulators Snail and Slug, concomitant with a decrease of N-cadherin and an increase of E-cadherin known to regulate stem-like properties. There was also an increase in cleaved caspase-3 levels, suggesting that the observed growth inhibition was due to apoptosis. Together, these findings suggest that Rb1 or CK in combination with a chemotherapeutic regimen may be a promising approach in cancer therapy.-
dc.languageeng-
dc.publisherThe University of Hong Kong (Pokfulam, Hong Kong)-
dc.relation.ispartofHKU Theses Online (HKUTO)-
dc.rightsThe author retains all proprietary rights, (such as patent rights) and the right to use in future works.-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.lcshGinseng - Therapeutic use-
dc.subject.lcshDrug resistance in cancer cells-
dc.subject.lcshOvaries - Cancer-
dc.titleRole of ginsenoside Rb1 and its metabolite compound K in attenuating chemoresistance and tumour-initiating properties of ovarian cancer cells-
dc.typePG_Thesis-
dc.identifier.hkulb5334847-
dc.description.thesisnameMaster of Philosophy-
dc.description.thesislevelMaster-
dc.description.thesisdisciplineBiological Sciences-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.5353/th_b5334847-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats